-
-
- Ar-Ge Birimi
- Endüstriyel Aşı Üretimi Birimi
- Aşı ve Bağışıklama Eğitimi Birimi
- Aşı Epidemiyolojisi Birimi
- Preklinik ve Klinik Araştırmalar ve Proje Koordinasyon Birimi
- Pandemi Riski Yaratan Enfeksiyon Etkenleri Epidemiyolojisi Birimi
- Biyolojik Terör Birimi
- Deney Hayvanları Üretim/Test ve Preklinik Araştırma Birimi
- Doku Kültür Koleksiyonu Viral ve Bakteriyel Kültür Bankacılığı Birimi
- Kalite Kontrol Laboratuvarı Birimi
- Eğitim, İdari ve Mali Hizmetler Birimi
-
-
-
- Duyurular
- Önemli Günler
- SSS
- İletişim
- Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up
- Analysis of participant-reported adverse events following the first dose of inactivated SARS-Cov-2 vaccine (TURKOVAC™) through telephone survey in Türkiye
- Tıp Tarihimizden Portreler: Dr. Reşat Rıza (Kor) (1877-1941)
- Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey
- Development of an Inactivated Vaccine against SARS CoV-2
- Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
- Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials
- Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC™) among General and High-Risk Population
- Development of an Inactivated Vaccine against SARS CoV-2
- Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial